Mechanisms of Pressure Relief in Glaucoma: Pharmacologic & Surgical Advances

Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Mechanisms of Pressure Relief in Glaucoma: Pharmacologic & Surgical Advances for Refractory POAG or Non-Adherence

Mechanisms of Pressure Relief in Glaucoma: Pharmacologic & Surgical Advances for Refractory POAG or Non-Adherence
Glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension.

Available credits: 1.25

Time to complete: 1.25 hours


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Glaucoma is the leading cause of irreversible vision loss worldwide and it is expected that the number of people affected by glaucoma will increase dramatically in coming decades due to the aging of the world’s population. Despite advances in ocular imaging and visual field testing, a substantial proportion of patients with glaucoma remain undiagnosed and present late in the course of their disease. At the same time, while several classes of drugs are used to manage patients with glaucoma, significant unmet needs persist in glaucoma care.

    In this CME/CE-certified enduring activity, glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension. Expert faculty will discuss the unmet clinical needs in glaucoma management and will review recently approved therapies together with those in the pipeline that may influence clinical decision-making, and may result in optimum outcomes for non-compliant patients or those refractory to medical therapy alone. Through discussion of creative clinical case scenarios, faculty will also highlight important treatment strategies for glaucoma that ophthalmologists can readily incorporate into clinical practice. These may include reduced complications with MIGS stents and ocular inserts vs. definitive, invasive trabeculectomy; recommendations for single and two-drug failure, noncompliance, and new delivery systems that allow sustained medication release.


  • Disclosure of Conflicts of Interest

    David S. Friedman, MD, PhD, MPH: Consulting Fees—Allergan, Nidek Ltd; Speaker—Alcon, Allergan
    Steven J. Gedde, MD: Consulting Fees—Alcon, Allergan; Grant Support—Abbott Medical Optics, National Eye Institute, Research to Prevent Blindness
    W. Daniel Stamer, PhD: Consulting Fees—Aerie, Glauconix, Precision Biosciences; Contracted Research—Aerie, Allergan, Inotek, Ironwood, Precision Biosciences

  • Target Audience

    This activity has been designed to meet the educational needs of Physicians, NPs, RNs, and PAs who treat patients with glaucoma.

  • Learning Objectives

    After completing this CME/CE activity, the participant will be able to:

    1. Assess the current healthcare needs of patients with open-angle glaucoma
    2. Interpret the new evidence surrounding the underlying mechanism of glaucoma and the subsequent discovery of new therapies that address deficiencies in the clinical care of glaucoma
    3. Discuss the published findings and the clinical significance of the latest surgical techniques and MIGS devices for glaucoma, including how each may be used to achieve IOP targets for a diverse range of patients

  • Accreditation and Credit Designation Statements


    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthmattersCME. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 0.4 pharmacotherapy contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.  


    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.


    The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The HealthmattersCME planners and managers have nothing to disclose.


    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Educational Partners

    This activity is jointly provided by Postgraduate Institute for Medicine and HealthmattersCME.


  • Commercial Support

    This activity is supported by independent educational grants from Aerie Pharmaceuticals, Inc., Alcon Pharmaceuticals Ltd., and Bausch & Lomb, Inc.


  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.